← Leaderboards
Erin A McClure
Medical University Of South Carolina
$9,972,633
Attributed
$11,238,156
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2014–25$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,138,156 · 8
FDA$100,000 · 2
By mechanism
R01$5,063,890 · 4
R37$4,228,359 · 1
K01$771,474 · 1
R34$659,933 · 1
R21$414,500 · 1
R13$100,000 · 2
Top collaborators
- Nathaniel Lee Baker2 shared
- Tracy Taylor Smith2 shared
- Jamie Brown1 shared
- Christie D Fowler1 shared
- Suchitra Krishnan-Sarin1 shared
- Jennifer Lynn Pearson1 shared
- Gideon St.Helen1 shared
- Rachel Lynn Tomko1 shared
Most similar at Medical University Of South Carolina
Same institution · by research overlap
- James Joseph Prisciandaro$8,640,417
- Kevin M Gray$28,834,568
- Nathaniel Lee Baker$621,713
Others in their field
Top investigators on “Participant”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$407,724,307
- Lawrence Corey · Fred Hutchinson Cancer Center$333,313,234
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Albert Lazzarini · California Institute Of Technology$300,431,866
Research focus
ParticipantAbstinenceUnited StatesBiochemicalLiteratureAdultTobaccoPrevalencePatient Self-ReportMarijuana UseCannabisTobacco Use CessationRecommendationSmokerProspectiveSmoking CessationMedicalSmokingTreatment TrialTreatment OutcomePublic HealthCigarette SmokingPharmacotherapyTobacco Use
Grant awards (28)
Prospective changes in patient-reported and objective functioning following reduction of cannabis use$686,692
R01 · FY2025 · DA
Evaluating a tobacco harm reduction strategy among clients enrolled in substance use disorder treatment$625,247
R01 · FY2025 · DA · contact PI
The impact of cannabis and tobacco/nicotine product co-use in young adults: Prospective cessation evaluation and substitution$614,771
R01 · FY2025 · CA · contact PI
Randomized controlled trial of varenicline to treat tobacco and cannabis co-use.$598,901
R01 · FY2025 · CA · contact PI
Determining the impact of cannabis use and severity on tobacco cessation outcomes: A prospective tobacco treatment trial$580,584
R37 · FY2025 · CA · contact PI
Evaluating a tobacco harm reduction strategy among clients enrolled in substance use disorder treatment$657,941
R01 · FY2024 · DA · contact PI
Randomized controlled trial of varenicline to treat tobacco and cannabis co-use.$602,786
R01 · FY2024 · CA · contact PI
The impact of cannabis and tobacco/nicotine product co-use in young adults: Prospective cessation evaluation and substitution$587,896
R01 · FY2024 · CA · contact PI
Determining the impact of cannabis use and severity on tobacco cessation outcomes: A prospective tobacco treatment trial$558,891
R37 · FY2024 · CA · contact PI
The impact of cannabis and tobacco/nicotine product co-use in young adults: Prospective cessation evaluation and substitution$689,656
R01 · FY2023 · CA · contact PI
Determining the impact of cannabis use and severity on tobacco cessation outcomes: A prospective tobacco treatment trial$592,830
R37 · FY2023 · CA · contact PI
Determining the impact of cannabis use and severity on tobacco cessation outcomes: A prospective tobacco treatment trial$605,225
R37 · FY2022 · CA · contact PI
Quantifying data-driven metrics of meaningful cannabis reduction$188,750
R21 · FY2022 · DA · contact PI
Determining the impact of cannabis use and severity on tobacco cessation outcomes: A prospective tobacco treatment trial$75,500
R37 · FY2022 · CA · contact PI
Determining the impact of cannabis use and severity on tobacco cessation outcomes: A prospective tobacco treatment trial$605,001
R37 · FY2021 · CA · contact PI
Quantifying data-driven metrics of meaningful cannabis reduction$225,750
R21 · FY2021 · DA · contact PI
SRNT 2021 Annual Meeting$50,000
R13 · FY2021 · FD
Determining the impact of cannabis use and severity on tobacco cessation outcomes: A prospective tobacco treatment trial$605,272
R37 · FY2020 · CA · contact PI
SRNT 2020 Annual Meeting$50,000
R13 · FY2020 · FD
Determining the impact of cannabis use and severity on tobacco cessation outcomes: A prospective tobacco treatment trial$605,056
R37 · FY2019 · CA · contact PI
Evaluating N-acetylcysteine as a pharmacotherapy for tobacco use disorder$183,030
R34 · FY2018 · DA · contact PI
Technological Innovations for the Remote Monitoring of Smoking in Adolescents$154,378
K01 · FY2018 · DA · contact PI
Evaluating N-acetylcysteine as a pharmacotherapy for tobacco use disorder$219,123
R34 · FY2017 · DA · contact PI
Technological Innovations for the Remote Monitoring of Smoking in Adolescents$154,378
K01 · FY2017 · DA · contact PI
Evaluating N-acetylcysteine as a pharmacotherapy for tobacco use disorder$257,780
R34 · FY2016 · DA · contact PI
Technological Innovations for the Remote Monitoring of Smoking in Adolescents$154,378
K01 · FY2016 · DA · contact PI
Technological Innovations for the Remote Monitoring of Smoking in Adolescents$154,378
K01 · FY2015 · DA · contact PI
Technological Innovations for the Remote Monitoring of Smoking in Adolescents$153,962
K01 · FY2014 · DA · contact PI